Cebranopadol is under clinical development by Tris Pharma and currently in Phase I for Substance (Drug) Abuse. According to GlobalData, Phase I drugs for Substance (Drug) Abuse have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cebranopadol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cebranopadol (GRT-6005) is under development for the treatment of cancer pain and substance drug abuse . It is an orally administered analgesic agent that exhibits a potent agonist activity on opioid receptor like -1 (ORL1) and mu opioid receptor.
It was also under development for the treatment of chronic nociceptive pain and chronic moderate to severe pain related to cancer, chronic pain due to diabetic peripheral neuropathy, post-operative pain in hallux valgus (Bunion), chronic pain due to knee osteoarthritis (OA), addiction and chronic low back pain
Tris Pharma overview
Tris Pharma discovers, develops and commercializes over-the-counter and generic products. The company’s pipeline product candidates include TRN-110, TRN-124, TRN-125, TRN-167, TRN-123, TRN-152, TRN-148, TRN-219, TRN-213 and TRN-226. Its generic products include colesevelam, dexmethylphenidate, dextroamphetamine, doxycycline Hyclate, doxycycline hyclate, droxidopa, febuxostat, hydrocodone, hydrocodone polistirex, lacosamide, methylphenidate, morphine sulfate and paliperidone ER. Tris Pharma is headquartered in South Brunswick, New Jersey, the US.
For a complete picture of Cebranopadol’s drug-specific PTSR and LoA scores, buy the report here.